Page 5,822«..1020..5,8215,8225,8235,824..5,8305,840..»

Mass. pharmacy owners got $16M in final months

Posted: Published on January 23rd, 2013

BOSTON (AP) -- The owners of a pharmacy linked to a fatal meningitis outbreak received more than $16 million in wages and payments as the company grew increasingly prosperous in its final months. The four family members, who served as the New England Compounding Center's directors, received the money between late December 2011 and late November 2012, according to a bankruptcy court filing. The largest payout went to the firm's majority shareholder, Carla Conigliaro, who received $8.7 million. The vast majority of the money paid to the owners was distributed before the outbreak of meningitis, an inflammation of the lining of the brain and spinal cord, was discovered in Tennessee in September. But an attorney for unsecured creditors in the case, including victims who received tainted injections of a drug made by the NECC, said it's distressing that the company had the money to clean up the conditions that led to the outbreak but never did it. "There was a substantial amount of cash available that could have been used to clean things up, to make things right, and instead was being taken by insiders," said attorney David Molton, of Brown Rudnick LLP, which represents the Official Committee of Unsecured … Continue reading →

Posted in Pharmacy | Comments Off on Mass. pharmacy owners got $16M in final months

RPT-INSIGHT-U.S. government investment gives flu vaccines a shot in the arm

Posted: Published on January 23rd, 2013

(Repeats story first published on Jan. 19) By Julie Steenhuysen CHICAGO, Jan 19 (Reuters) - Fighting the flu may soon get easier. As early as next year, more modern and more effective vaccines will hit the market, thanks to investments by the U.S. government and pharmaceutical companies. And even bigger scientific advances are expected in the next decade, including a "universal" flu vaccine given every five to 10 years that would fight many strains of a virus, making annual shots all but obsolete. Experts say it could take eight to 10 more years of testing before a universal flu vaccine would be ready. Meanwhile, they expect advances that could still incrementally improve the level of protection vaccines offer and shorten manufacturing times. In the last 12 months, the U.S. Food and Drug Administration has approved two new seasonal flu vaccines that protect against four predominant strains of flu instead of three. One is a shot made by GlaxoSmithKline (Other OTC: GLAXF - news) and the other is a nasal spray made by AstraZeneca (NYSE: AZN - news) . In late November (Xetra: A0Z24E - news) , the FDA approved Novartis (Berlin: NOT.BE - news) ' new flu vaccine grown in … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on RPT-INSIGHT-U.S. government investment gives flu vaccines a shot in the arm

Government investment gives flu vaccines a shot in the arm

Posted: Published on January 23rd, 2013

Government investment gives flu vaccines a shot in the arm January 22, 2013 (Reuters) Fighting the flu may soon get easier. As early as next year, more modern and more effective vaccines will hit the market, thanks to investments by the U.S. government and pharmaceutical companies. And even bigger scientific advances are expected in the next decade, including a "universal" flu vaccine given every five to 10 years that would fight many strains of a virus, making annual shots all but obsolete. Experts say it could take eight to 10 more years of testing before a universal flu vaccine would be ready. Meanwhile, they expect advances that could still incrementally improve the level of protection vaccines offer and shorten manufacturing times. In the last 12 months, the U.S. Food and Drug Administration has approved two new seasonal flu vaccines that protect against four predominant strains of flu instead of three. One is a shot made by GlaxoSmithKline and the other is a nasal spray made by AstraZeneca. In late November, the FDA approved Novartis' new flu vaccine grown in cultures of dog kidney cells instead of the conventional chicken eggs, a faster and more reliable manufacturing process that could help … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Government investment gives flu vaccines a shot in the arm

Top Three Regenerative Medicine Companies Targeting Ischemic Conditions

Posted: Published on January 23rd, 2013

As we discussed in our first article on elite regenerative medicine companies, there are several methodologies to delineating the cream of the crop. In this exercise, we will take a look at the impact that regenerative medicine technologies can have on ischemic conditions where tissue in the heart, brain, organs or limbs are damaged as a result of restricted blood flow and identify some of the most innovative companies that have a strong upside based on the products and technologies they are developing, stage of development, and current valuations. Ischemic conditions are expansive, covering common conditions such as stroke, heart disease and peripheral vascular disease (which in severe cases can result in critical limb ischemia, requiring amputation of digits or limbs). The economic impact of these types of conditions is also substantial. Research by the American Heart Association indicates that cardiovascular disease (most of which is ischemic in nature) comprises more than $300 billion in healthcare related expenses annually, accounting for more than 17% of total healthcare related expenses in the U.S. Furthermore, these conditions impose a huge quality of life burden for patients and their families, and therefore are areas of great unmet medical need. From a company and … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Top Three Regenerative Medicine Companies Targeting Ischemic Conditions

VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference

Posted: Published on January 23rd, 2013

SOUTH SAN FRANCISCO, CA--(Marketwire - Jan 22, 2013) - VistaGen Therapeutics, Inc. ( OTCBB : VSTA ) ( OTCQB : VSTA ), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced that Shawn K. Singh, CEO of VistaGen, will present at Noble Financial Capital Markets' Ninth Annual Equity Conference. Mr. Singh will discuss VistaGen's progress and unique opportunities to apply its stem cell technology platform, Human Clinical Trials in a Test Tube, for drug rescue, predictive toxicology and drug metabolism screening. Mr. Singh's presentation will be delivered at 12:30 pm EST on Wednesday, January 23, 2013, at the Hard Rock Hotel in Hollywood, Florida. Webcast Information: At the time of the presentation, a live audio and video webcast of Mr. Singh's presentation and a copy of the presentation materials will be available on VistaGen's website at http://www.vistagen.com and Noble Financial's website at http://www.noblefcm.com. Investors and analysts should register approximately 10 minutes prior to the start of the presentation to ensure timely access. Viewing the presentation will require Microsoft Silverlight (a free download is available from the presentation link). About VistaGen Therapeutics VistaGen is a biotechnology company applying human pluripotent stem cell … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference

Vitro Biopharma Launches New Stem Cell Products to Accelerate Bone Growth

Posted: Published on January 23rd, 2013

GOLDEN, Colo., Jan. 22, 2013 (GLOBE NEWSWIRE) -- Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced the launch of a series of products with application to accelerated bone growth, fracture healing and development of new osteoporosis drugs. The new products are osteoblasts derived from human adult stem cells known as mesenchymal stem cells (MSCs). These cells lead to bone growth and function to maintain bone density and in the recovery from bone fractures. Osteoporosis, a disease characterized by reduction in bone density is thought to result from decreased osteoblast production by MSCs; bone growth necessary for repair of bone fractures also depends on osteoblasts. The new products include native and labeled MSC-derived human osteoblasts in various formats including fluorescent and magnetic cells for use in different imaging methods. For example, magnetic osteoblast cells labeled with super paramagnetic iron oxide (SPIO) may be used for in-vivo imaging of osteoblasts using magnetic resonance imaging (MRI) a common clinical imaging procedure. The availability of native and multiply-labeled osteoblasts provides numerous options to conduct in-vitro high throughput screening cell assays and to coordinate these studies with in-vivo studies. Dr. Jim Musick, Vitro Biopharma's President & CEO, said, "We are pleased to announce commercial availability … Continue reading →

Comments Off on Vitro Biopharma Launches New Stem Cell Products to Accelerate Bone Growth

Tissue engineering – Video

Posted: Published on January 23rd, 2013

Tissue engineering http://www.stemcellsarthritistreatment.com Cartilage damage is irreversible. To date, only reconstructive surgical procedures such as joint replacement are the only option available for significant cartilage loss. Cell therapy, using transplantable stem cells with scaffolds, can possible regenerate new cartilage matrix. The potential of mesenchymal stem cells to differentiate into chondrocytes (cartilage cells) with the aid of the proper environment and growth factors makes these cells very attractive for tissue engineering purposes. The combination of three key ingredients... stem cells, growth factors, and a framework is required. http By: Nathan Wei … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Tissue engineering – Video

Palestinian prisoner on hunger strike for ill-son

Posted: Published on January 22nd, 2013

Ramallah: The fasting Palestinian prisoner Tareq Hussain Awad Qedan is dedicating his hunger strike, launched 52 days ago, to save the life of his only son, Khalid, who suffers complete muscular dystrophy. Tareq, who is from the village of Arrabah near Jenin and is currently serving an Israeli administrative detention order, is refusing medical fluids and gets only very small quantities of water. His medical condition has recently deteriorated rapidly. Since day one of his hunger strike, Tareq has been refusing the fluids and going the hardest way in his fast, said Moawiyah, a brother of Tareq told Gulf News. Treatment is not available for Tareqs four-year-old only son Khalid in the Palestinian Territories and Tareq himself should accompany his son to Ukraine to start treatment based on the stem cells therapy, he said. Article continues below Moawiyah said that this kind of treatment was extremely expensive, but Tareqs family has declared they were all ready to sell all their properties to finance Khalids treatment. We have a great need to see Tareq walk out free to start the kids treatment instantly, he said. He said that the Israeli authorities know that Tareq had not been politically active before his … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Palestinian prisoner on hunger strike for ill-son

New Efforts Underway to Improve Care for Veterans with Epilepsy

Posted: Published on January 22nd, 2013

ATLANTA, Jan. 22, 2013 /PRNewswire/ --Today, the U.S. Department of Veterans Affairs' Epilepsy Centers of Excellence (ECoE), biopharmaceutical company UCB and health data-sharing website PatientsLikeMe announce a new study to better understand what factors improve health outcomes for veterans with epilepsy. The ECoE has recently completed a pilot study focused on collecting and sharing real world, patient-reported data on seizure frequency and severity, treatment adherence, patient and physician dialogue and overall quality of life. The study is now open and available to all veterans living with epilepsy at http://www.poemstudy.org. "This collaborative effort, with partners from government and private industry, provides an exciting opportunity to improve the outcomes of the thousands of veterans with epilepsy. Our work together may also deliver insights into how we can improve the care for anyone with epilepsy," says study lead and ECoE's John Hixson, M.D. As part of their initial partnership to help epilepsy patients, which began in 2010, PatientsLikeMe and UCB conducted a study of members of the PatientsLikeMe epilepsy community that showed that people with epilepsy who joined PatientsLikeMe better understood their own seizures and improved adherence to their medications.1,2 The new study of veterans will integrate validated clinical outcome measures alongside the … Continue reading →

Comments Off on New Efforts Underway to Improve Care for Veterans with Epilepsy

BroadcastMed Spotlights Pediatric Epilepsy Treatment at NewYork-Presbyterian

Posted: Published on January 22nd, 2013

FARMINGTON, Conn.--(BUSINESS WIRE)-- ORLive.com, BroadcastMeds premier surgical broadcasting website, is proud to present a webcast on the diagnosis and treatment of pediatric epilepsy from the Pediatric Comprehensive Epilepsy Center at NewYork-Presbyterian Phyllis and David Komansky Center for Childrens Health. At NewYork-Presbyterian, patients and their families work with a team of experts to determine the best care possible for the patient. Providing revolutionary diagnostic techniques and comprehensive treatment options, the team works together to address lifelong needs for the epilepsy patient. This webcast will be premiering January 23rd at NOON EST. Watch Pediatric Epilepsy: Diagnosis and Treatment here. To learn more about this and other web events visit ORLive.com. You can sign up for our weekly e-newsletter and follow us on Facebook and Twitter. Plus, to see numerous health videos from a wide-range of specialties, check out our YouTube Channel. About BroadcastMed, Inc. BroadcastMed is an online medical broadcasting company. We help the Worlds leading hospitals and medical device companies create and deliver trusted educational content to physicians. Our clients rely on us to deliver measurable results by expanding their reach through the BroadcastMed syndication network which includes ORLive.com, ranked among the top three online destinations for physicians. More here: BroadcastMed … Continue reading →

Comments Off on BroadcastMed Spotlights Pediatric Epilepsy Treatment at NewYork-Presbyterian

Page 5,822«..1020..5,8215,8225,8235,824..5,8305,840..»